6634 Stock Overview
A biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Sinew Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$49.00 |
| 52 Week High | NT$80.90 |
| 52 Week Low | NT$43.85 |
| Beta | 0.98 |
| 1 Month Change | -9.09% |
| 3 Month Change | 5.83% |
| 1 Year Change | -25.42% |
| 3 Year Change | -43.61% |
| 5 Year Change | 153.23% |
| Change since IPO | -1.61% |
Recent News & Updates
Shareholder Returns
| 6634 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -4.9% | -0.1% | -1.5% |
| 1Y | -25.4% | 6.6% | 10.0% |
Return vs Industry: 6634 underperformed the TW Pharmaceuticals industry which returned 6.6% over the past year.
Return vs Market: 6634 underperformed the TW Market which returned 10% over the past year.
Price Volatility
| 6634 volatility | |
|---|---|
| 6634 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.7% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6634 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6634's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 51 | Kai-Min Chu | www.sinewpharma.com |
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630 drug, for which is in Phase II clinical trial. It is also developing SNP-810 is in phase II clinical trial for use in Pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States.
Sinew Pharma Inc. Fundamentals Summary
| 6634 fundamental statistics | |
|---|---|
| Market cap | NT$3.49b |
| Earnings (TTM) | -NT$150.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-23.2x
P/E RatioIs 6634 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6634 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$150.37m |
| Earnings | -NT$150.37m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6634 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/18 19:28 |
| End of Day Share Price | 2025/03/18 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sinew Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.